








Welcome to the AWTTC Newsletter!

Quarterly updates to keep you informed of our latest news and work.

Featuring news for October–December 2018 from:

	Welsh Analytical Prescribing Support Unit (WAPSU)	2
	Yellow Card Centre (YCC) Wales	3
	Welsh National Poisons Unit (WNPU)	3
	Patient Access to Medicines Service (PAMS)	4



This newsletter is published on the AWTTC website. Please email awttc@wales.nhs.uk if you would like us to add you to our mailing list or if you would like to give any feedback.



Best Practice Day presentations available to watch online

| November 2018

Videos of each of the presentations from the Best Practice Day 2018, with slides from the day incorporated, are now available to watch online. Videos, slides decks and additional information are also available to view on share.org.

[Read more...](#)

AWTTC attends RPS Conference

| November 2018

AWTTC was invited to attend the 8th Royal Pharmaceutical Society (RPS) Wales Medicines Safety Conference on 22nd November 2018.

As well as having an exhibitor stand to showcase the wide spectra of activities undertaken by AWTTC, the Yellow Card Centre Wales team delivered one of the morning's workshop sessions entitled 'To be or not to be... safe' (see page 3).

[Read more...](#)



- Analysing prescribing data and developing medicines optimisation resources...

➤ Read more...

Guide to Prescribing Gluten-free Products

| November 2018

This guide, updated in November, aims to support GPs and other healthcare professionals in the management of patients with coeliac disease, and aid the decision-making process for prescribing approved gluten-free foods.

➤ Read more...

Antipsychotics in Dementia Audit

| December 2018

A new national audit has been published aiming to ensure prescribing of antipsychotics in patients aged 65 years and over with a diagnosis of dementia is in line with current NICE guidance, and supporting identification of patients where it may be appropriate to reduce or stop their antipsychotic prescription.

➤ Read more...

Medicines Identified as Low Priority for Funding - Paper 2

| December 2018

This document is part of ongoing work to minimise the prescribing of medicines with low clinical effectiveness or where more cost-effective treatments are available. Four medicines/ medicine groups have been identified for this document:

- > omega-3 fatty acid compounds,
- > oxycodone and naloxone combination product,
- > paracetamol and tramadol combination product,
- > perindopril arginine.

➤ Read more...

Coming soon - Biosimilar Best Practice Day 2019

| Coming soon

The latest NPI report has shown considerable variation in the uptake of biosimilar products across health boards in Wales, with the potential for significant cost savings if all health boards prescribed in line with the best performing health board.

A Biosimilar Best Practice Day, due to be held at Cardiff City Stadium on 21 January 2019, will provide a forum to share good practice initiatives, prescribing data, behavioural change methodologies and procurement and commissioning information to support wider uptake of biosimilars in NHS Wales.

➤ Read more...

Quarterly NPI report

| December 2018

The first National Prescribing Indicator (NPI) report for 2018-2019 has been published, analysing data for the quarter ending June 2018. NPIs for 2018-2019 include indicators for primary and secondary care, and have been categorised as safety, stewardship or efficiency indicators. The majority of NPIs with a threshold showed improvement across Wales in line with the aim of each indicator, compared with the equivalent quarter of the previous year.

➤ Read more...

Table 1: Health Boards/Practices Achieving Indicator Targets/Thresholds

Indicator	Health Board/Practice	Target	Actual	Percentage
Safety	AWTTC	100%	100%	100%
	Cardiff	100%	100%	100%
	Cardiff and Vale	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale	100%	100%	100%
	Cardiff West and Vale	100%	100%	100%
	Cardiff and Vale Health Board	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale Health Board	100%	100%	100%
	Cardiff West and Vale Health Board	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale Health Board	100%	100%	100%
Stewardship	AWTTC	100%	100%	100%
	Cardiff	100%	100%	100%
	Cardiff and Vale	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale	100%	100%	100%
	Cardiff West and Vale	100%	100%	100%
	Cardiff and Vale Health Board	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale Health Board	100%	100%	100%
	Cardiff West and Vale Health Board	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale Health Board	100%	100%	100%
Efficiency	AWTTC	100%	100%	100%
	Cardiff	100%	100%	100%
	Cardiff and Vale	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale	100%	100%	100%
	Cardiff West and Vale	100%	100%	100%
	Cardiff and Vale Health Board	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale Health Board	100%	100%	100%
	Cardiff West and Vale Health Board	100%	100%	100%
	Cardiff Health Board	100%	100%	100%
	Cardiff South and Vale Health Board	100%	100%	100%

Table 2: Number of Yellow Cards Submitted by Secondary Care - Quarter ending June 2018 versus quarter ending June 2017

Indicator	2017-2018	% Change
Cardiff	2	20%
Cardiff and Vale	12	14%
Cardiff Health Board	42	20%
Cardiff South and Vale	7	47%
Cardiff West and Vale	22	36%
Cardiff and Vale Health Board	28	25%
Cardiff Health Board	2	53%
Cardiff South and Vale Health Board	200	45%

Table 3: Number of Yellow Cards Submitted by Health Boards per 100,000 Population

Health Board	2017-2018	2018-2019	% Change
Cardiff	25	22	12%
Cardiff and Vale	140	130	7%
Cardiff Health Board	30	111	371%
Cardiff South and Vale	110	102	-7%
Cardiff West and Vale	15	9	-40%
Cardiff and Vale Health Board	130	83	-36%
Cardiff Health Board	117	111	-5%
Cardiff South and Vale Health Board	2	23	105%
Cardiff West and Vale Health Board	480	297	-38%



- Monitoring adverse reactions to medicines...

[> Read more...](#)

Yellow Card Supporter Pledge

| November 2018

YCC Wales has launched a Yellow Card Supporter Pledge. Members of the public and healthcare professionals are invited to visit the YCC Wales website and make the pledge to help make medicines safer and support the Yellow Card Scheme.



[> Read more...](#)

YCC at the RPS Medicines Safety Conference

| November 2018

YCC Wales held a breakout session at the RPS conference entitled 'To be or not to be... safe', presented by Dr Laurence Gray, Dr Lynette James, and Dr Mark Stacey, who explored how pharmacovigilance, safety culture and human factors influence patient safety.



[> Read more...](#)

ADR Awareness Week

| November 2018

YCC Wales joined 32 medicines regulators from around the world in promoting Adverse Drug Reaction (ADR) Awareness Week. The theme of this year's campaign was 'Reporting side effects helps the safe use of medicines for babies, children and pregnant women'.



[> Read more...](#)



- Providing 24-hour poisons advice to healthcare professionals...

[> Read more...](#)

WNPU hosts 2018 Update in Medical Toxicology Course

| October 2018

WNPU hosted their two-day Update in Medical Toxicology Course in Cardiff on 19-20 October 2018. The course was delivered by a group of twelve leading consultants in clinical toxicology covering topics including:

- Calcium channel blocker overdose
- Nerve and chemical warfare agents
- Recreational drugs and novel psychoactive substances
- Poisonous plants
- Novel oral anticoagulants and their antidotes
- Teratology
- Radiation poisoning

The course was illustrated with a wide range of practical, real-life case studies, and consultants in toxicology were on hand to liaise with delegates over the two days. The next course is planned for Autumn 2019.

[> Read more...](#)



WeMeReC

Welsh Medicines Resource Centre
Canolfan Adnoddau Moddion Cymru

- Providing education in therapeutics, prescribing and behavioural change...

[› Read more...](#)



PAMS

Patient Access to Medicines Service
Mynediad Claf at Wasanaeth Meddyginiaethau

- Supporting health technology appraisals and coordinating the outputs of IPFR panels across Wales...

[› Read more...](#)

New medicines advice

| November-December 2018

PAMS supports the All Wales Medicines Strategy Group (AWMSG) to assess and monitor new medicines in Wales.

In November, Welsh Government approved advice from AWMSG for semaglutide (Ozempic®), conestat alfa (Ruconest®) and ipilimumab (Yervoy®).

[› Read more...](#)

In December, Welsh Government approved advice from AWMSG for bicittegravir/emtricitabine/tenofovir alafenamide (Biktarvy®), fosaprepitant (IVEMEND®) and tiotropium (Spiriva® Respimat®).

[› Read more...](#)

Also in December, Welsh Government approved advice from AWMSG for dolutegravir/rilpivirine (Juluca®) and brivaracetam (Briviact®).

[› Read more...](#)

AWMSG Masterclass for the pharmaceutical industry

| November 2018

AWTTC hosted the annual AWMSG Masterclass for the pharmaceutical industry at Cardiff City Stadium on 22 November 2018. The primary goal of these annual Masterclass days is to promote engagement from the pharmaceutical industry

and answer any questions they may have regarding the appraisal process in Wales. It also provides an opportunity to network with people from AWMSG and AWTTC.



[› Read more...](#)



All Wales Therapeutics & Toxicology Centre
Canolfan Therapiwteg
a Thocsicolog Cymru Gyfan

Contact us

Academic Building,
University Hospital Llandough,
Penlan Road, Penarth,
Vale of Glamorgan CF64 2XX

Telephone: 029 2071 6900

Email: awttc@wales.nhs.uk

Web: www.awttc.org